An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Acadia Pharmaceuticals (ACAD) has appointed Adora Ndu, Pharm.D., J.D., to its Board of Directors. With over 15 years in regulatory affairs and clinical development, Dr. Ndu brings significant expertise to support Acadia's strategic initiatives, particularly as the company prepares to launch its second commercial product, trofinetide, for Rett syndrome. Her prior leadership roles include Chief Regulatory Affairs Officer at BridgeBio and Group VP at BioMarin Pharmaceutical. Dr. Ndu's background in rare diseases complements the existing board, emphasizing a strong focus on central nervous system disorders.
Positive
Appointment of Adora Ndu enhances board expertise in regulatory affairs and drug development.
Dr. Ndu's experience in rare diseases supports upcoming product launch of trofinetide.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Adora Ndu, Pharm.D., J.D. to its Board of Directors. Dr. Ndu is a biopharma executive with more than 15 years of experience in regulatory affairs and clinical development.
Dr. Adora Ndu. (Photo: Business Wire)
“We are pleased to welcome Dr. Ndu to Acadia’s Board,” said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia’s Board of Directors. “Dr. Ndu’s significant regulatory and clinical development experience, combined with her extensive background in rare disease nicely complements the skill sets of our current membership. Her expertise will be invaluable as we continue to pursue our strategic initiatives in disorders affecting the central nervous system, particularly as the company prepares to launch its second commercial product, trofinetide, for the treatment of Rett syndrome.”
“I am honored to join Acadia’s Board of Directors. I look forward to collaborating with its members alongside Acadia’s talented management team as they develop and commercialize innovative new therapies addressing high unmet needs in the field of CNS,” said Dr. Ndu.
Since 2022, Dr. Ndu has served as the Chief Regulatory Affairs Officer of BridgeBio. Previously, she was the Group Vice President, Head of Worldwide Research and Development Strategy, Scientific Collaborations and Policy at BioMarin Pharmaceutical. She brings over 15 years of complementary experience in drug development and regulatory affairs. Dr. Ndu has spent eight years in various leadership roles in the biopharmaceutical sector. Her expertise includes regulatory strategy, patient engagement, prescription drug promotion, and policy for U.S. and international markets. Additionally, Dr. Ndu spent eight years at the U.S. Food and Drug Administration, Center for Drug Evaluation and Research, where she progressed in leadership serving most recently as Director for the Division of Medical Policy Development and Commander in the U.S.Public Health Service. She has been involved in the registrations of multiple products globally and is a respected thought leader in regulatory science, having played a significant role in developing and evaluating guidance, as well as shaping regulatory policy. Dr. Ndu currently serves on the board of DBV Technologies. Dr. Ndu received her doctorate in pharmacy from Howard University’s College of Pharmacy and a law degree from the University of Maryland.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Rett syndrome and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.
Media Contact:
Acadia Pharmaceuticals Inc. Deb Kazenelson
(818) 395-3043
media@acadia-pharm.com
Investor Contact:
Acadia Pharmaceuticals Inc. Mark Johnson, CFA
(858) 261-2771
ir@acadia-pharm.com
Source: Acadia Pharmaceuticals Inc.
FAQ
Who is the new board member appointed at Acadia Pharmaceuticals?
Adora Ndu, Pharm.D., J.D., has been appointed to the Board of Directors at Acadia Pharmaceuticals.
What experience does Adora Ndu bring to Acadia Pharmaceuticals?
Adora Ndu brings over 15 years of experience in regulatory affairs and clinical development, having held leadership roles at BridgeBio and BioMarin.
What is the significance of Dr. Ndu's appointment to Acadia Pharmaceuticals?
Dr. Ndu's appointment is significant as it strengthens Acadia's board with expertise in rare diseases and regulatory strategy, particularly for upcoming product launches.
What product is Acadia Pharmaceuticals preparing to launch?
Acadia Pharmaceuticals is preparing to launch trofinetide for the treatment of Rett syndrome.
